Publications, Abstract Presentations and Selected Research Initiatives

Andrew D. Luber, Pharm.D.

Original Articles


Condoluci D, Andrew M, Luber A. Improvements in CD4 cell counts following the switch from tenofovir to abacavir in a patient with persistent lymphopenia despite continued non-detectable viral load measurements. AIDS Reader. 2008; 18: 410-412.


Expert Reviews


**Luber AD.** Adefovir (PMEA) and adefovir dipivoxil (Bis-POM PMEA). Current drugs investigational drugs (on-line database). 1996.


**Textbook Chapters**


**Luber AD.** Contribution Author: Clinical Cases: Clinical Pharmacy and Therapeutics Workbook for Herfindal and Gourley’s Textbook of Therapeutics: Drug and Disease Management. 6th Edition. 1996.

**Letters**


Abstract Presentations


Guglielmo BJ, Corelli RL, Flaherty JF, Kostiuk KA, Luber AD, Robinson MD, Jacobs RA. An antimicrobial monitoring system improves therapeutic efficacy and reduces toxicity in


Selected Research Projects and Grants

2007 – Co-Principal Investigator. A Randomized, Open-label, Four-Arm, Three-Period, Drug Interaction Study to Assess Steady-State Plasma Amprenavir (APV) and Raltegravir (RTG) Pharmacokinetics Following Co-administration of Fosamprenavir (FPV) 1400mg BID and RTG 400mg BID for 14 Days and Following FPV 700mg BID + RTV 100mg BID and RTG 400mg BID for 14 Days in Healthy Adult Subjects. (Investigator Initiated Trial). GlaxoSmithKline.

2006 – Co-Principal Investigator. Assessment of Nelfinavir (NLF) trough concentrations in the presence of the proton pump inhibitor omeprazole (OMP). (Investigator Initiated Trial). Pfizer Laboratories.

2005 – Co-Principal Investigator. Retrospective evaluation of CD4 cell counts among patients with non-detectable viral load measurements who are receiving non-ddI containing TDF based HAART. (Investigator Initiated Trial). No study sponsor.

2005 – Co-Principal Investigator. Evaluation of the steady state pharmacokinetics of amprenavir (when given as fos-amprenavir and fos-amprenavir/ritonavir) and tenofovir DF when given alone and together in healthy volunteers. (Investigator Initiated Trial). GlaxoSmithKline.


2004 – **Co-Principal Investigator.** Pharmacokinetic evaluation of duration of ritonavir boosting among HIV-infected patients taking twice-daily saquinavir-ritonavir. (Investigator Initiated Trial). *Roche Pharmaceuticals.*

2003 – **Co-Principal Investigator.** Evaluation of the anti-lipogenic effects of tenofovir DF (TDF) when combined with trizivir (zidovudine (AZT), lamivudine (3TC) and abacavir (ABC)) and combivir (zidovudine (AZT) and lamivudine (3TC)). (Investigator Initiated Trial). *Gilead Sciences.*

2003 – **Co-Principal Investigator.** Evaluation of Combivir (Zidovudine (ZDV) plus Lamivudine (3TC)) in Combination With Tenofovir DF (TDF) Among Antiretroviral Treatment Naive HIV-infected Patients. (Investigator Initiated Trial). *Gilead Sciences.*

2003 – **Sub Investigator.** A Phase I open-label, dose-escalation study of MDX-010 administered monthly as immunotherapy in patients infected with Human Immunodeficiency Virus. *Medarex Pharmaceuticals.*


2002 – **Co-Principal Investigator.** Viral dynamics of 3TC when given as once-daily monotherapy over 7 days. (Investigator Initiated Trial). *GlaxoSmithKline.*


2002 – **Co-Principal Investigator.** Evaluation of switching tenofovir DF (TDF) for protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) agents among patients receiving HAART with non-detectable viral load measurements and elevated cholesterol and/or triglyceride values. (Investigator Initiated Trial). *Gilead Sciences.*

2002 – **Co-Principal Investigator.** Evaluation of trizivir (Zidovudine (ZDV), abacavir (ABC), lamivudine (3TC)) and tenofovir DF (TDF) as HAART for HIV infected patients with current or underlying reverse transcriptase (RT) resistance. (Investigator Initiated Trial). *GlaxoSmithKline.*

2002 – **Sub Investigator - A phase I/II randomized, double-blind, active-controlled, dose escalation study of the safety, tolerance, pharmacokinetics, and antiviral activity of GS 7340-02 in antiretroviral-naive patients who are chronically infected with HIV-1. *Gilead Sciences.*
2002 – Co-Principal Investigator – A multicenter Phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of S-1360 given as open-label monotherapy administered to treatment experienced HIV-1 infected subjects. GlaxoSmithKline and Shionogi Pharmaceuticals.

2002 – Co-Principal Investigator - A Phase II, randomized, placebo-controlled study to compare antiviral effect, safety, tolerability and pharmacokinetics of four oral doses of S-1360 versus placebo over 10 days in ART-naïve HIV-1 infected adults. GlaxoSmithKline and Shionogi Pharmaceuticals.

2002 – Sub Investigator - A Phase Ib double-blind, placebo-controlled, randomized study on the safety and tolerability of Z-100 in early HIV-1 infected patients. Zeria Pharmaceuticals.

2002 – Sub Investigator - A Phase II, open-label, multicenter, randomized, parallel group, 14 day pilot study of monotherapy with zidovudine 600 mg once daily compared to zidovudine 300 mg twice daily in HIV-infected, antiretroviral-naïve subjects. GlaxoSmithKline.


2001 – Co-Principal Investigator – Assessment of nelfinavir (NLF) peak and trough plasma levels among HIV-infected patients with stable but measurable viral load measurements between 1,000 and 5,000 copies/ml despite receiving dual nucleoside analogue therapy in combination with twice-daily NLF antiretroviral regimens. (Investigator Initiated Trial). Agouron Pharmaceuticals.

2001 – Sub-Investigator – A Phase II study evaluating the safety and efficacy of capravirine versus placebo in HIV-infected patients failing a non-nucleoside reverse transcriptase inhibitor containing regimen. Agouron Pharmaceuticals.

2001 – Co-Principal Investigator - Efficacy and tolerability of efavirenz (EFV) in highly antiretroviral experienced HIV-positive patients. (Investigator Initiated Study). DuPont Pharmaceuticals.

2000 – Principal Investigator - Effects on cholesterol and triglyceride levels after switching from non-amprenavir protease inhibitor (PI) antiretroviral regimens to amprenavir (APV) antiretroviral regimens. (Investigator Initiated Study). Vertex Pharmaceuticals.

2000 – Principal Investigator – Assessment of inter- and intra-patient amprenavir (APV) drug exposure when given as part of HAART. (Investigator Initiated Study). Vertex Pharmaceuticals.


2000. Principal Investigator – A three center, prospective evaluation of patient adherence when taking twice-daily nelfinavir as compared to non-nucleoside reverse transcriptase inhibitor containing antiretroviral regimens. (Investigator Initiated Study). Agouron Pharmaceuticals.


1996 – Sub-Investigator – Drug-drug interaction study with intravenous cidofovir (CDV), and either trimethoprim/sulfamethoxazole (TMP/SMX), didanosine (DDI), or fluconazole (FLU) in HIV-infected individuals Gilead Sciences.


